This investigation was initiated due to a customer reporting a false susceptible voriconazole (vrc) result with candida glabrata bp survey strain (myco 2018-2a) on vitek® 2 v7.01 ast-ys08 card.The customer submitted the isolate for evaluation.Identification of the submitted organism was confirmed and testing included two cards from customer lots (2880600203 called cl1 and 2880653103 called cl2) of ast-ys08 cards, as well as one card from a random lot (2880585403 rl).The reference method used for the development of the incriminated drug was performed in parallel of vitek 2 testing : -broth microdilution (bmd), which was the method used for voriconazole development (vrc01n formulary) : vrc mic = 4 mg/l r, so within two doubling dilutions can be s/i/r.-on vitek 2 v7.01 ast-ys08 card (aes parameters : casfm eucast 2016 + phenotypic) : *on cl1, the vrc value (2 mg/l intermediate) is within essential agreement compared to the reference mic (bmd - 4 mg/l resistant) but lead to a minor error of category.*on cl2, the vrc value (1 mg/l susceptible) is within essential agreement within two (2) doubling dilutions with the reference mic (bmd- 4 mg/l resistant), but lead to a very major error of category.*on rl, the vrc value (>/= 8 mg/l resistant) is within essential agreement within one (1) doubling dilution with the reference mic (bmd- 4 mg/l resistant), without category error.Conclusion : *the false susceptible voriconazole on ast-ys08 card is confirmed in-house only on cl2.Note : the reference mic equal to 4 mg/l can be s, i or r within two (2) doubling dilutions, which can explain the susceptible result.This is a borderline strain.*cards performed as intended and no further action is required.
|